These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11019837)

  • 21. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
    Lee SH; Lee MH; Lee JH; Min YH; Lee KH; Cheong JW; Lee J; Park KW; Kang JH; Kim K; Kim WS; Jung CW; Choi SJ; Lee JH; Park K
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):122-8. PubMed ID: 15682073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.
    Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Yu-Wang ; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):632-8. PubMed ID: 19361756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow.
    Hägglund H; Ringdén O; Remberger M; Lönnqvist B; Sparrelid E; Tammik L; Kumlien G
    Bone Marrow Transplant; 1998 Jul; 22(2):131-6. PubMed ID: 9707019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome.
    Barge RM; Brouwer RE; Beersma MF; Starrenburg CW; Zwinderman AH; Hale G; Waldmann H; den Ottolander GJ; Falkenburg JH; Willemze R; Fibbe WE
    Bone Marrow Transplant; 2001 May; 27(10):1053-8. PubMed ID: 11438820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of human leucocyte antigen disparity and graft lymphocytes on allogeneic engraftment and survival after umbilical cord blood transplant in adults.
    van Heeckeren WJ; Fanning LR; Meyerson HJ; Fu P; Lazarus HM; Cooper BW; Tse WW; Kindwall-Keller TL; Jaroscak J; Finney MR; Fox RM; Solchaga L; Forster M; Creger RJ; Laughlin MJ
    Br J Haematol; 2007 Nov; 139(3):464-74. PubMed ID: 17910637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.
    Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L
    Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transplantation of haematopoietic stem cells derived from cord blood, bone marrow or peripheral blood: a single centre matched-pair analysis in a heterogeneous risk population.
    Schönberger S; Niehues T; Meisel R; Bernbeck B; Laws HJ; Kögler G; Enzmann J; Wernet P; Göbel U; Dilloo D
    Klin Padiatr; 2004; 216(6):356-63. PubMed ID: 15565551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
    Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
    Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors.
    Yamasaki S; Henzan H; Ohno Y; Yamanaka T; Iino T; Itou Y; Kuroiwa M; Maeda M; Kawano N; Kinukawa N; Miyamoto T; Nagafuji K; Shimoda K; Inaba S; Hayashi S; Taniguchi S; Shibuya T; Gondo H; Otsuka T; Harada M;
    Bone Marrow Transplant; 2003 Sep; 32(5):505-10. PubMed ID: 12942097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.
    Novitzky N; Mohamed R
    Exp Hematol; 1995 Dec; 23(14):1661-6. PubMed ID: 8542962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Ringdén O; Schaffer M; Le Blanc K; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):128-34. PubMed ID: 14750078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
    Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
    Ozcan M; Ustün C; Akçağlayan E; Akan H; Arslan O; Ilhan O; Beksaç M; Gürman G; Demirer T; Arat M; Celebi H; Konuk N; Uysal A; Koç H
    Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
    Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
    Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.